Navigation Links
FTC Ends Investigation of CVS Caremark
Date:1/12/2012

WOONSOCKET, R.I., Jan. 12, 2012 /PRNewswire/ -- CVS Caremark Corporation (NYSE: CVS) announced today that the Federal Trade Commission (FTC) has concluded its investigation under the Federal Trade Commission Act into the company's business practices.  The investigation has resulted in CVS Caremark entering into a consent order that relates to certain business practices of a subsidiary of Longs Drug Stores Corporation, which took place prior to the acquisition of Longs by CVS Caremark in October 2008.  There were no allegations of antitrust law violations or anti-competitive behavior related to CVS Caremark's business practices or its products or service offerings.  In addition, the Company has received a formal letter from the FTC closing all other aspects of the investigation.

(Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO )

Pursuant to the consent order, CVS Caremark will deposit $5 million into a fund that will be used to compensate consumers who purchased coverage for the 2008 plan year from a Medicare Part D Prescription Drug Plan sponsored by Rx America, a subsidiary of Longs.  The fund is being established as a result of Rx America inadvertently posting on a website maintained by the Centers for Medicare and Medicaid Services (CMS) inaccurate pricing information for certain generic drugs.  In addition, CVS Caremark agreed on a go forward basis to refrain from making any misrepresentations regarding drug pricing information relating to affiliate sponsored Medicare Part D plans. The consent order will be published in the Federal Register and is subject to comment for 30 days.

"CVS Caremark is pleased to have reached an agreement with the FTC that ends the investigation and enables us to continue our focus on offering unique, innovative products a
'/>"/>

SOURCE CVS Caremark
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
3. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
7. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
11. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  The Healthcare Analytics Summit 2014 ... Salt Lake City , Sept. 24-25 ... respected healthcare organizations in the U.S. and beyond.  HAS ... industry conference devoted to providing immersive learning experiences on ... of both accountable care initiatives and population health ...
(Date:7/29/2014)... IRVING, Texas , July 29, 2014 /PRNewswire/ ... three new web-based applications with breakthrough interactive features ... and workflows for members of Children,s Hospital Association.  ... under the Novation Optimize Solutions umbrella – Value ... of how Novation helps organizations address the most ...
(Date:7/29/2014)... DIEGO , July 29, 2014   ... Nancy Thornberry to its board of ... franchise head, Diabetes and Endocrinology for Merck & ... strategy and overall pipeline management in diabetes, osteoporosis, ... initiated and co-led the program that resulted in ...
Breaking Medicine Technology:Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3
... ASSERT Trial Presented at EULAR, BARCELONA, Spain, ... at the European League Against Rheumatism (EULAR),Annual ... with,ankylosing spondylitis (AS) who received REMICADE(R) (infliximab),over ... In addition, REMICADE-treated patients showed sustained,reductions in ...
... Research, TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- ... that,(1) demonstrate that Azixa(TM) (MPC-6827) is effective in ... (2) reveal a,mechanism by which MPC-6827 exerts its ... by cellular proteins known to be involved,in cancer ...
Cached Medicine Technology:Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 2Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 3Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 4Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 5Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 6Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 7Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 8Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 9Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 10Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 11Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 12New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 2New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 3New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 4New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 5New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 6
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Although the bite of ... heal well if left alone, an expert notes. ... an adverse reaction to a brown recluse spider bite, ... Poison Center, particularly since these potentially dangerous bites are ... for us to do nothing. The [bite] has classic ...
(Date:7/29/2014)... improvement measures in eight of the 10 hospitals in ... have found a way to reduce kidney injury in ... 7-15 percent of these patients who undergo a coronary ... which can result in death or rapid decline in ... a study published in the July issue of ...
(Date:7/29/2014)... New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. , The study finds that the majority ...
(Date:7/29/2014)... Avenidas is always looking for ways to ... non-profit agency is doing just that with the Third Annual ... event gives seniors the opportunity to learn about how they ... a variety of fun activities, including a Tai Chi demonstration, ... In addition, there will be food tastings, courtesy of Lyfe ...
(Date:7/29/2014)... kidney transplants receive steady follow-up care, the living ... make follow-up care more accessible, UC San Francisco ... to launch the first program in the country ... to living kidney donors. , UCSF will provide ... than 4,500 Walgreens pharmacies and Healthcare Clinic at ...
Breaking Medicine News(10 mins):Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Reducing kidney injury using a quality improvement method 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:Caring for donors 2Health News:Caring for donors 3
... - Researchers from the Boston University School of Medicine ... a $3.5 million grant from the National Institute on ... treat, and retain" paradigm in Eastern Europe among HIV-infected ... narcology (addiction) care. The project will be known as ...
... of The Gerontologist urges aging ... in their work. The publication also identifies research priorities ... in addition to providing several strategies that scholars can ... that non-white minorities will make up 42 percent of ...
... Mozes HealthDay Reporter , WEDNESDAY, July 20 (HealthDay ... people to develop cancer, new British research says. Among ... leukemia or melanoma appears to go up about 16 percent ... "Taller women in our study had increased risk of a ...
... , THURSDAY, July 21 (HealthDay News) -- A new U.S. ... to use the Internet for medical information, and whites are ... the findings released Thursday by the U.S. National Center for ... as likely as Hispanics to search for health information online. ...
... National Nanotechnology Initiative,s (NNI) released four reports that ... focusing on various issues in the nanotechnology environmental, ... series was a part of an ongoing strategy ... from industry, academia, and the Federal Government to ...
... the first time created a way of measuring how much force ... advance is expected to have significant implications for legal forensics. ... the force applied during a stabbing and come up with the ... work has been published in the International Journal of Legal ...
Cached Medicine News:Health News:BUSM/BMC researchers awarded $3.5 million grant from the NIDA 2Health News:Minority participants crucial to effective aging studies 2Health News:Study Contends Taller People at Heightened Cancer Risk 2Health News:Study Contends Taller People at Heightened Cancer Risk 3Health News:Women, Whites Most Likely to Seek Health Info Online: Survey 2Health News:NNI releases 4 workshop reports from the nanoEHS Series 2Health News:University of Leicester develops test for classifying force used in bottle stabbings 2Health News:University of Leicester develops test for classifying force used in bottle stabbings 3
... offers the ease and comfort you've come to ... users in clinical trials agreed that the BD ... depth settings allow you to choose the best ... of lancets, the device also helps eliminate the ...
... StaRRsed-III is a system that measures ... samples. This rate may be relevant ... The sedimentation rate is measured in ... typically used in high-volume settings such ...
... The StaRRsed Compact is a system ... human blood samples. This rate may ... patients therapy. The sedimentation rate is ... hence is typically used in high-volume ...
MiniVes has been specifically designed for the doctors office and near patient testing and it uses normally freshly collected blood that shall be mixed manually by 15 complete inversion of the tube a...
Medicine Products: